TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00769561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback-Based Cognitive Behavioral Treatment
Description: The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental treatment with occlusal splint (OS)
Description: Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment.
Study: NCT02745470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Description: Colorless, transparent liquid contained in a glass prefilled syringe pen-like injection (GLP-1 receptor agonist)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline injection before performing fMRI
Study: NCT00921024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-101
Description: intravenous
Study: NCT04005573

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3
Description: VD3 50000 IU/ week for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega 3- FA
Description: Omega 3 FA group 300 mg once daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3 and omega- 3FA
Description: 50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: no intervention is given
Study: NCT02207569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreValve Evolut R TAVR system
Study: NCT01833845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: weight-based doses (1000 mg/day administered BID \[twice daily\] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects \> 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)
Study: NCT02935985

Intervention type: OTHER
Intervention: Point-of-care bio-markers (cTnI, hsCRP, D-Dimer) and biological parameters (CBC, glucose, cholesterol, LDL cholesterol, triglycerides, fibrinogen)
Description: Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days.
Study: NCT00921024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: intravenous
Study: NCT02735564

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bariatric Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Study: NCT02405403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714 PET
Description: \[18F\]DPA-714 Positron Emission Tomography
Study: NCT01493427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Description: Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
Study: NCT02225210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Loading dose:0.4μg.kg-1 Maintenance dose :0.2\~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05\~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5\~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
Study: NCT02503033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: Oral administration, once daily
Study: NCT02965651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECA System
Description: The ECA system, named Gabby, included content pertaining to stress management, nutrition and physical activity as well as dialogue scripts and media such as meditations. The scripts included motivational interviewing dialogue: dialogue to simulate shared decision making interactions and additional longitudinal interaction using techniques such as goal setting, problem solving, tips, and homework. Gabby was available on a web browser through a username and secure password login.
Study: NCT04559113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Injectable Product
Description: 1. 0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~2. Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day.
Study: NCT02323074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Computer Interface
Study: NCT04245228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Coach
Description: Trained in motivational interviewing who will call the patient weekly for 12 sessions for an approximately 30-minute intervention
Study: NCT02428764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.
Study: NCT04316351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab + Pemetrexed + Anlotinib
Description: Toripalimab 240 mg iv d1 + anlotinib 12mg po d1-d14 + pemetrexed 500mg / m2 d1 Q3W for 4 cycles, followed by Toripalimab 240mg iv d1 + anlotinib 12mg po d1 + pemetrexed 500mg / m2 d1 Q3W for another 31 cycles (up to a total of 35 cycles).~If there is no disease progression, patients will receive anlotinib po 12mg d1-d14 + pemetrexed 500mg / m2 d1, Q3W for maintenance therapy until PD per RECIST v1.1 or loss of clinical benefit.
Study: NCT02323074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Computer Interface

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Brain Computer Interface
Study: NCT03052205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
Study: NCT01981252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT02334423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin, Type A
Description: Botulinum toxin, Type A

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sterile, unpreserved saline
Description: Placebo
Study: NCT01635777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: 2.5 mg/kg/day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: 2.5 mg/kg/day for 8 weeks
Study: NCT03758859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate eyedrops
Description: sodium hyaluronate eyedrops administered - route ocular -topical
Study: NCT01035359

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External fixation
Description: Bridging external fixation of a distal radius fracture with an optional addition of k-wire(s)
Study: NCT02860052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB208 2%
Description: Apply once daily to one or both feet for 14 days
Study: NCT01035359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volar plate
Description: Operation of distal radius fracture with open reduction and fixation with a plate from the volar side of the wrist.
Study: NCT02988362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL068 16/10mg
Description: Candesartan 16mg and Amlodipine 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 16mg and Amlodipine 10mg
Study: NCT02860052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB208 4%
Description: Apply once daily to one or both feet for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB208 16%
Description: Apply once daily to one or both feet for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Apply once daily to one or both feet for 14 days
Study: NCT04239924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paramedic Coaching
Description: The intervention is an adaptation of the evidence-based REACH program, specific coaching content is delivered by paramedics in 1-2 hour in-home sessions and over the phone throughout a 12-month period.
Study: NCT02926898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 (Fenfluramine Hydrochloride)
Description: ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL.~\*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo
Study: NCT02396329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Study: NCT03069989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348
Description: Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
Study: NCT02396329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Study: NCT03827083

Intervention type: OTHER
Intervention: cerebral pulse oximetry
Description: Cognitive Functions by Cerebral Pulse Oximetry After General Anesthesia and Spinal Anesthesia

Intervention type: OTHER
Intervention: cerebral pulse oximetry
Description: Cognitive Functions by Cerebral Pulse Oximetry After General Anesthesia and Spinal Anesthesia
Study: NCT03069989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348
Description: Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FBA-A20FMDV2
Description: Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [18F]-FBA-A20FMDV2
Description: Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FBA-A20FMDV2
Description: Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [18F]-FBA-A20FMDV2
Description: Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
Study: NCT03184246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: videolaryngoscopy (GlideScope) will be used for intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: direct laryngoscopy will be used for intubation
Study: NCT05047744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Touch Dual Mobility CMC I Prosthesis
Description: Surgery
Study: NCT00067340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse
Description: women received daily chlorhexidine oral rinses for two weeks prior to delivery of the infant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Description: Women were asked to chew xylitol chewing gum three times per day following the birth of their infant for up to two years postpartum
Study: NCT03710954

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: All volunteers were evaluated by numerical pain scale and Fuzzy scale. This procedure was performed to compare the efficacy of the Fuzzy Scale demonstrating greater accuracy of quantification of skeletal muscle pain
Study: NCT00276302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.~For both Schedule A and B doses will be administered ≥ 72 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.~For both Schedule A and B doses will be administered ≥ 72 hours apart.
Study: NCT00982345

Intervention type: DRUG
Group type: OTHER
Intervention: quetiapine (Seroquel XR)
Description: Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
Study: NCT04321889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: defurocumarinized bergamot loaded in a nanotechnological essential oil release system
Description: Patients will be treated either with placebo cream or with defurocumarinized bergamot loaded in a nanotechnological system of essential oil release in the pharmaceutical form of cream 2 times a day for 4 weeks. The subject will be monitored throughout the treatment and for at least 4 weeks after the end of the treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nanotechnological system loaded with placebo cream
Study: NCT02855255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NHS 1-1 smoking cessation programme.
Description: Smoking cessation using cognitive behavioural therapy/motivational interviewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group smoking cessation programme
Description: Smoking cessation using Allen Carr's Easyway method being delivered in a spoken form.
Study: NCT01100788

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short chain fructo-oligosaccharide (scFOS) 5 g
Description: Dietary Supplement: scFOS 5 g~Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment without scFOS fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short chain fructooligosaccharide (scFOS) 8 g
Description: Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
Study: NCT01673386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Study: NCT00812253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous insulin
Description: Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous insulin
Description: Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
Study: NCT02407444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment & leg cycling
Description: All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale.
Study: NCT00945243

Intervention type: DEVICE
Group type: OTHER
Intervention: Zero-P
Description: The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
Study: NCT02371616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium sodium phosphosilicate
Description: 5% w/w calcium sodium phosphosilicate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium sodium phosphosilicate
Description: 5% w/w calcium sodium phosphosilicate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Description: 1426 ppm fluoride as sodium fluoride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: 1426 ppm fluoride as sodium monofluorophosphate
Study: NCT02576899

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy for PTSD and Tobacco Use
Description: ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Freedom From Smoking
Description: The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
Study: NCT02470741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00485836

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab injection 0.3 mg
Description: Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab injection 0.5 mg
Description: Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Study: NCT04211376

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study: NCT00511719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Description: 48U

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actrapid
Description: 24IU
Study: NCT04539418

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin K 2
Description: Patients will be monitored during the whole protocol.
Study: NCT01871805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive alectinib as described in the arm descriptions.
Study: NCT04539418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K 2
Description: Patients will be monitored during the whole protocol.
Study: NCT02308046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terconazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01181167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edoxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin sodium
Study: NCT04499885

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin oil gastric lavage
Description: Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric lavage with saline and sodium bicarbonate 8.4%
Description: Gastric lavage with saline and sodium bicarbonate 8.4%
Study: NCT02657330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBP-101
Description: Subcutaneous drug, escalating dose cohorts